KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Debt: 2015-2024

Historic Total Debt for BeOne Medicines (ONC) over the last 10 years, with Dec 2024 value amounting to $1.0 billion.

  • BeOne Medicines' Total Debt rose 56.57% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 56.57%. This contributed to the annual value of $1.0 billion for FY2024, which is 14.90% up from last year.
  • According to the latest figures from FY2024, BeOne Medicines' Total Debt is $1.0 billion, which was up 14.90% from $886.0 million recorded in FY2023.
  • BeOne Medicines' 5-year Total Debt high stood at $1.0 billion for FY2024, and its period low was $507.0 million during FY2022.
  • For the 3-year period, BeOne Medicines' Total Debt averaged around $803.7 million, with its median value being $886.0 million (2023).
  • As far as peak fluctuations go, BeOne Medicines' Total Debt spiked by 229.55% in 2020, and later decreased by 19.48% in 2022.
  • Over the past 5 years, BeOne Medicines' Total Debt (Yearly) stood at $518.7 million in 2020, then increased by 21.41% to $629.7 million in 2021, then declined by 19.48% to $507.0 million in 2022, then soared by 74.74% to $886.0 million in 2023, then climbed by 14.90% to $1.0 billion in 2024.